Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4Thoracic 2Plasma cell 2Head & Neck 2Gastrointestinal 2CNS 2NET 1Lymphoid 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Lymphoma 305Lymphoma, Non-Hodgkin 226Lymphoma, Large B-Cell, Diffuse 220Lymphoma, Follicular 200Leukemia, Lymphocytic, Chronic, B-Cell 168Lymphoma, B-Cell 148Recurrence 124Burkitt Lymphoma 117Lymphoma, Mantle-Cell 112Leukemia, Myeloid, Acute 106Leukemia 102Hodgkin Disease 102Multiple Myeloma 95Lymphoma, B-Cell, Marginal Zone 87Neoplasms 80Myelodysplastic Syndromes 69Lymphoma, T-Cell, Peripheral 62Hematologic Neoplasms 61Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 58Lymphoma, T-Cell 51Lymphoma, T-Cell, Cutaneous 44Waldenstrom Macroglobulinemia 41Leukemia, Biphenotypic, Acute 35Mycosis Fungoides 31Lymphoproliferative Disorders 30Leukemia, B-Cell 30Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Breast Neoplasms 28Myeloproliferative Disorders 26

Interventions

repotrectinib 1Suspensions 1Capsules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Solitary Fibrous Tumors × Lymphoid × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡